Informations générales (source: ClinicalTrials.gov)
Evaluation of Efficacy and Tolerance of Fludrocortisone (Flucortac) in the Treatment of Orthostatic Neurogenic Hypotension
Interventional
Phase 4
H.A.C. PHARMA (Voir sur ClinicalTrials)
juillet 2020
juin 2024
29 juin 2024
To evaluate the efficacy of a 4-week fludrocortisone (FLU) treatment on systolic blood
pressure depression after 5 minutes of active orthostatism in patients with neurogenic
orthostatic hypotension (HON) symptomatic, despite treatment with non-drug measures with
or without midodrine.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Broca-La Rochefoucauld-La Collégiale | Olivier HANON, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Diagnosis of orthostatic hypotension (HO), ie a blood pressure drop> 20 and / or 10
mmHg within 3 minutes after active and symptomatic lifting
- Patient suffering from a neurological disease
- orthostatic neurogenic hypotension persistent and symptomatic despite non-drug
measures
- Diagnosis of orthostatic hypotension (HO), ie a blood pressure drop> 20 and / or 10
mmHg within 3 minutes after active and symptomatic lifting
- Patient suffering from a neurological disease
- orthostatic neurogenic hypotension persistent and symptomatic despite non-drug
measures
- Hypersensitivity to FLU or any of its excipients
- non orthostatic neurogenic hypotension
- History of proven heart failure
- History of left ventricular systolic dysfunction
- Uncompensated hypokalemia
- Patient with poorly balanced Grade 3 hypertension
- Pregnant patient at the time of inclusion
- Nursing patient